Summit Therapeutics Share Discussion Threads

[football] 31/8/2017 12:04

That's the best bits from the latest RNs

Utrophin Modulation Programme for DMD

Ezutromid - Highlights


-- Completed enrolment into PhaseOut DMD in May 2017, which triggered a
$22.0 million development milestone payment as part of Summit's licence
and collaboration agreement with Sarepta Therapeutics, Inc ('Sarepta').
PhaseOut DMD is a 48-week, open label Phase 2 clinical trial that has
enrolled 40 patients at sites in the UK and US. The trial aims to
establish proof of concept of ezutromid and is evaluating a range of
muscle structure, muscle health and functional endpoints.

-- Expecting to report full 24-week data analysis from PhaseOut DMD in Q1
2018. This data set will include 24-week biopsy data from all patients
who provide a 24-week biopsy sample (approximately 20 patients). In
addition, Summit expects to report 24-week MRI and functional data from
all 40 patients in the trial. Top-line data from the complete 48-week
clinical trial are expected in Q3 2018.


CDI Programme

Ridinilazole - Highlights


-- Presented preclinical data at ASM Microbe 2017, including data showing
that ridinilazole was very active against all 200 clinical isolates of C.
difficile and was more potent than the marketed broad-spectrum
antibiotics vancomycin and metronidazole. In addition, it was reported
that a low-level, stable ridinilazole mutant resistant strain was
developed to help further elucidate ridinilazole's mechanism of action.

-- Exploring various funding options for the Phase 3 development programme
as the Company seeks to maximize the value of ridinilazole. These
possible options include entering into a collaboration with a third party
and/or securing meaningful non-dilutive funding from government entities
and philanthropic, non-government and not for profit organisations.

-- Planning to report data from an exploratory Phase 2 clinical trial
evaluating ridinilazole against the antibiotic fidaxomicin later this
year. A key objective of the trial is to determine the relative impact on
the patients' microbiomes following treatment with ridinilazole compared
to fidaxomicin.


Operational Highlights


-- Strengthened R&D team with Chief Operating Officer Dr David Roblin
expanding his role to include serving as Chief Medical Officer and the
appointments of Dr Anne Heatherington as Head of Clinical Development &
Quantitative Sciences and Dr Dave Powell as Head of Research. These
appointments, announced in May 2017, will help ensure the Company has the
leadership, depth of knowledge and expertise needed to support its
clinical and preclinical pipeline.


Financial Highlights


-- Cash and cash equivalents at 31 July 2017 of GBP28.3 million compared to
GBP28.1 million at 31 January 2017.

-- Cash balance at 31 July 2017 reflects receipt of $22.0 million (GBP17.2
million) development milestone payment from Sarepta during the three
months ended 31 July 2017.

-- Profit for the six months ended 31 July 2017 of GBP6.2 million compared
to a loss of GBP11.9 million for the six months ended 31 July 2016
(adjusted).

[waterloo01] 31/8/2017 10:47

lol. Hopefully Eric has not been given a staring role. More of the straight man to Glyn's routine!

[football] 31/8/2017 10:41

What ever they put out it can't be any more disappointing than the last presentation or can it


gla

[chrisatrdg] 31/8/2017 10:38

Hi waterloo01 I hope it will not be a damp squib as last time but some positive news clearly based on yesterdays NASDAQ performance there is some interest in the US maybe in anticipation of today.

[waterloo01] 31/8/2017 10:33

We know the numbers will be good but will we get an update on ETZ and as importantly RDZ next steps. Might be a damp squib or we could re rate and see us testing some of the earlier highs? Would be good to see the back of £2.00 and move forward.

[football] 30/8/2017 22:39

Q2 2017 Summit Therapeutics Plc Earnings Conference call
31 Aug, 2017

[chrisatrdg] 30/8/2017 21:46

Interesting close on the NASDAQ up 5.47% to $12.87 & at todays exchange rate comes out at £2.00 for UK purposes somewhat ahead of todays AIM mid point close of £1.85.In addition units transacted were 12,536 so not insignificant and green all day.Good to see such interest prior to Thursday's results day with the added opportunity of ability to have questions asked.Lets hope some momentum can be achieved Thursday.

Not wishing to put a damper on things but Autumn starts 22nd September 2017 which means Summer ends on the 21st September so still plenty of time for Glyn's deal to be 'this summer'.

Link on Summit website for todays results call:

[chrisatrdg] 25/8/2017 16:50

Wow - I think Summit have got these results out quicker than at any other time well done Summit team.

Next week is now a good opportunity for people to ask where we are with the various timetable's i.e. DMD & C-Diff.

[football] 25/8/2017 14:31

Summit Therapeutics plc Summit Therapeutics Plc : Notice Of Results
25/08/2017 2:30pm
UK Regulatory (RNS & others)


TIDMSUMM

Summit Therapeutics plc

("Summit" or the "Company")

SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER
AND HALF YEAR ENDED 31 JULY 2017 ON 31 AUGUST 2017

Oxford, UK, -- August 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ:
SMMT), the drug discovery and development company advancing therapies
for Duchenne muscular dystrophy and Clostridium difficile infection,
will announce its financial results for the second quarter and half year
ended 31 July 2017 on 31 August 2017.

Summit will host a conference call the same day at 1:00pm BST / 8:00am
EDT. Conference call information will be included in the second quarter
and half year results press release and a replay of the call will also
be available through the Company's website, www.summitplc.com.

[chrisatrdg] 23/8/2017 21:13

Maybe people think that the summer is over but no C-Diff deal - slightly tongue in cheek.

[football] 23/8/2017 15:43

Up in the US yesterday and flatlining their today so while we down so much here today?

[hugus maximus] 23/8/2017 12:06

Agree Luminous ... at the moment the NASDAQ is equivalent to around £1.98 and no "reported" sells of significance here. Perhaps someone sold a significant holding that the MMs report next month. I never cease to be amazed by the degree of manipulation?

[luminoso] 23/8/2017 11:01

pathetic volumes to cause a 7p fall, IMO, and no fall on nasdaq to base it on either.
£/$ exchange rate deterioration may have prompted some of it, I guess. Pound getting trashed all the time despite reasonable data out of the UK recently.

[hugus maximus] 22/8/2017 22:22

Thanks Freedosh ... I'll take a look back through the thread re: CRISPR, but still potentially a few years for EZD to enjoy success if the wind blows in the right direction.

[freedosh] 22/8/2017 20:36

Hugus. I wrote a little while back on the DMD curative potential for CRISPR
In-vivo will take years but the potential for pre implantation correction exists now. For current patients I feel a conservative estimate for overcoming the problems and approval to be 10 years plus
Waterloo01. Yes FDA rejected PTC for the USA.
I remain positive that our approach is theoretically the best for now.

[waterloo01] 22/8/2017 18:16

It's still quacking though. I need to look it up, but fairly sure it's for the nonsense mutation specifically, didn't work very well but got conditional approval in the EU but told to go away last time by FDA. Or am I confusing it with another player? Freedosh?

[hugus maximus] 22/8/2017 18:10

Indeed ... on the 28th Sept. I'd assumed PTC's Ataluren was a dead duck ... am I correct in remembering there was a fatality during the trials?

[waterloo01] 22/8/2017 17:57

This should be interesting. Let's see what parent pressure does this time. FDA in a difficult position, as IMO they would kick this one straight out, but with the SRPT presidance, how will they play it. Process will be a dry run for when it's Summits term.

[hugus maximus] 22/8/2017 14:19

An interesting summary of Sarepta (One of the leader lines: "The $2.41 billion 'scientifically elegant placebo'") and mention of competition from another approach coming into view : "CRISPR - the method used to target genetic abnormalities ... to target DMD"

Although this is still a good way behind Summit trials, does anyone have knowledge of this and what potential CRISPR presents in long term?

[hugus maximus] 21/8/2017 23:17

Still some upward support on the NASDAQ. Role on September and anticipated news re: C Diff.

[football] 16/8/2017 08:54

Like I posted yesterday quick to market down from the US but very slow to take it back up

[luminoso] 15/8/2017 16:31

They took it down, they'll take it up, and then they'll take it down again....depending on the geo-political situation at the time. With volumes low due to the holiday season, this is always a volatile period they can exploit. Good luck to them. When the Indian Summer comes and C.Diff news arrives, it will be another story altogether.

[chrisatrdg] 15/8/2017 16:08

Just looked at the NASDAQ & it would be good if we can get back to $12.50 soon currently it is $12.36.

Edit: NASDAQ close $12.50.

[luminoso] 15/8/2017 09:55

Just trader chimps on nasdaq taking advantage of silly season.

[timw3] 15/8/2017 08:11

Heads up Seller cleared at AAOG... $800m spud in 4 weeks!!

AAOG without doubt in play now seller out with that 1m sell printed after hours.

Fincapp valuations:

Mengo hit 750bopd - £70m MCAP - £1
Djeno hit 10k bopd - £750m MCAP - £10

So £11 potential vs 28p share price

Current market cap is only £10m once cash is stripped out.

£10m cap vs $1billion potential...

No brainer at these levels.

60p+ target at least prior to spud in 4 weeks